The company
Oramed Pharmaceuticals Inc.
ORMP · Nasdaq
ORMP stood above a rising 150-day average in 50 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 3.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Just dropped out
- Weeks in an uptrend
- out for 1
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $2.1M
- Officials’ trades on record
- 4
- Institutions holding
- 81 (+22)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 50 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
4 disclosed lines: House 4, Senate 0, executive 0; 2 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Brad Knott House: U.S. House ClerkNC13 | sold | $15k–$50k | 10 Jan 2025filed 25 Feb 2025 |
| Andrew R. Garbarino House: U.S. House ClerkNY02 | sold | $1k–$15k | 14 Jan 2022filed 14 Jan 2022 |
| Andrew R. Garbarino House: U.S. House ClerkNY02 | sold | $1k–$15k | 1 Oct 2021filed 3 Nov 2021 |
| Andrew R. Garbarino House: U.S. House ClerkNY02 | bought | $1k–$15k | 23 Apr 2021filed 24 May 2021 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Joshua HexterCOO & CBO | sold | 30,000at $4.51 | 1 Oct 2026filed 2 Oct 2026 |
| Avraham GabayChief Financial Officer | sold | 20,000at $4.51 | 1 Oct 2026filed 2 Oct 2026 |
| Avraham GabayChief Financial Officer | sold | 73,360at $4.51 | 1 Jul 2026filed 2 Jul 2026 |
| Joshua HexterCOO & CBO | sold | 137,000at $4.46 | 1 Jul 2026filed 2 Jul 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Aquamarine Financial (Cayman) Ltdadded · filed 12 Aug 2026 | 2,512,175$12.1M | +399,863+18.9% |
| Gem Investment Advisors, LLCadded · filed 11 Aug 2026 | 1,998,802$9.6M | +358,733+21.9% |
| MERCER GLOBAL ADVISORS INCunchanged · filed 11 Aug 2026 | 1,910,540$9.2M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 1,608,111$7.7M | +1,515,919+1644.3% |
| Murchinson Ltd.reduced · filed 14 Aug 2026 | 1,290,294$6.2M | -25,000−1.9% |
| BML Capital Management, LLCreduced · filed 7 Aug 2026 | 866,269$4.2M | -2,300,962−72.6% |
| BOOTHBAY FUND MANAGEMENT, LLCreduced · filed 14 Aug 2026 | 578,638$2.8M | -22,078−3.7% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 500,690$2.4M | +476,408+1962.0% |
| GOLDMAN SACHS GROUP INCnew · filed 14 Aug 2026 | 253,293$1.2M | +253,293 |
| STATE STREET CORPnew · filed 7 Aug 2026 | 242,100$1.2M | +242,100 |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.